通过PABPC1相分离进行选择性转化控制,调节慢性髓性白血病的爆发性危机和治疗阻力
Chenguang Sun1,2, Xi Xu3,4, Zhongyang Chen1
1State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Key Laboratory of RNA and Hematopoietic Regulation, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Nature cell biology
|March 19, 2025
概括
聚A结合蛋白细胞质蛋白1 (PABPC1) 驱动慢性髓性白血病 (CML) 爆发危机的进展. 抑制PABPC1可以克服氨酸激酶抑制剂的耐药性,并抑制CML的进展.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 铁氨酸激酶抑制剂 (TKIs) 转化慢性髓性白血病 (CML) 治疗.
- 然而,TKI耐药性和进展到爆发危机 (BC) 仍然是重大的临床挑战.
- 转化控制越来越被认为对癌症进展至关重要.
研究的目的:
- 确定CML爆发危机进展的新型驱动因素.
- 研究CML中翻译控制的作用.
- 探索PABPC1作为克服CML中TKI耐药性的治疗点.
主要方法:
- 高通量CRISPR-Cas9查以确定CML进展的驱动因素.
- 分析PABPC1在mRNA翻译效率和凝结物形成中的作用.
- 在体外和体内评估PABPC1抑制对CML细胞增殖和疾病进展的影响.
- 对克服TKI耐药性的PABPC1抑制剂的评估.
主要成果:
- PABPC1被确定为在爆发危机阶段CML进展的关键驱动因素.
- PABPC1通过形成生物分子凝聚物来增强白血病产生的mRNA的翻译.
- PABPC1抑制抑制了CML扩散和疾病进展,对正常血液形成的影响最小.
- 在临床前模型中,鉴定的PABPC1抑制剂有效抑制了BC进展,并克服了TKI耐药性.
结论:
- PABPC1是CML爆发危机中的选择性翻译增强剂.
- 向PABPC1提供了一个有前途的策略,以克服TKI耐药性和治疗晚期CML.
- PABPC1的遗传或药理抑制表明了CML的治疗潜力.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Negative Regulator Molecules
35.1K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Separation of Sister Chromatids
3.5K
At the transition from prophase to metaphase, there is a reduction in cohesion along the chromosomal arms, resulting in the resolution of sister chromatids. However, residual cohesin connections remain to hold the sister chromatids together until the transition from metaphase to anaphase. The residual connection prevents any premature separation of sister chromatids, blocking the risks of aneuploidy within the daughter cells.
At the onset of anaphase, separase, a proteolytic enzyme, is...
At the onset of anaphase, separase, a proteolytic enzyme, is...
3.5K


